Document is current
Any future updates will be listed below
-
Authors
Vitillo, Loriana https://orcid.org/0000-0002-7184-1793
Anjum, Fabiha
Hewitt, Zoe
Laing, Owen
Ababneh, Nidaa A.
Baker, Duncan
Barbaric, Ivana
Coffey, Peter J.
-
Funding
Funding for this research was provided by:
UK Regenerative Medicine Platform (MR/L012537/1)
UK Regenerative Medicine Platform (MR/R015724/1)
Medical Research Council (G1000730)
Deanship of Scientific Research, University of Jordan (Grant No. 2022/19)
Lincy Foundation (P12761)
California Institute of Regenerative Medicine (G1000730)
King Abdullah II Design and Development Bureau (Grant No. 8/2019)
- License Information
-
More Information
Article History
Received: 2 February 2024
Accepted: 29 January 2025
First Online: 21 February 2025
Declarations
:
: Derivation of the MasterShef-7 cell line was performed in the Stem Cell Derivation Facility at the Centre for Stem Cell Biology, University of Sheffield, under the Human Fertilisation and Embryology Authority (HFEA) licence R0115-8-A (Centre 0191) and Human Tissue Authority (HTA) licence 22510. The embryo used to derive MasterShef-7 (frozen embryo) was donated from an assisted conception units, following fully informed consent, with no financial benefit to the donors, and was surplus or unsuitable for their IVF treatment. Derivation of the hIPSCs JUCTCi010-A, B and C cell lines were performed at the Cell Therapy Center, University of Jordan, as described previously [] following ethical approval and patient informed consent.
: Not applicable.
: Z.H. is a co-founder and CEO of Regenerative Cell Therapy Consulting Limited. I.B. is a member of the Scientific Advisory Boards of WiCell and Broken String Biosciences.
